ChemoMetec A/S (CPH:CHEMM)

ChemoMetec Cash Flow Statement

Financials in millions DKK. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	186.41	136.28	178.67	159.47	88.35
Depreciation & Amortization	11.17	9.82	13.93	13.8	12.98
Other Amortization	10.37	7.39	6.46	6.33	5.79
Loss (Gain) From Sale of Assets	-	-0	0.08	-0.09	0.83
Other Operating Activities	12.88	-11.38	-4.49	14.24	10.27
Change in Accounts Receivable	-	-	11.04	-15.22	-15.2
Change in Inventory	-	-	-45.85	-36.68	-5
Change in Accounts Payable	-	-	0.53	8.31	0.28
Change in Other Net Operating Assets	-13.36	-13.11	-6.22	26.7	9.59
Operating Cash Flow	207.45	129	154.15	176.86	107.9
Operating Cash Flow Growth	60.81%	-16.31%	-12.84%	63.91%	49.83%
Capital Expenditures	-29.87	-20.95	-21.18	-39.1	-11.25
Cash Acquisitions	-20.79	-	-	-	-
Sale (Purchase) of Intangibles	-34.87	-22.58	-19.64	-16.82	-13.37
Other Investing Activities	-	0.04	-0.02	-0.13	-0.06
Investing Cash Flow	-85.52	-43.49	-40.83	-56.05	-24.68
Long-Term Debt Issued	0.52	0.32	-	0.43	0.92
Long-Term Debt Repaid	-5.89	-1.62	-2.86	-1.73	-0.85
Net Debt Issued (Repaid)	-5.36	-1.3	-2.86	-1.3	0.07
Common Dividends Paid	-69.6	-104.42	-	-69.61	-26.1
Other Financing Activities	-	-	-0.07	1.89	-
Financing Cash Flow	-74.96	-105.72	-2.93	-69.01	-26.04
Foreign Exchange Rate Adjustments	-1.26	-0.22	-2.84	7.11	-4.01
Net Cash Flow	45.7	-20.43	107.55	58.92	53.17
Free Cash Flow	177.58	108.06	132.97	137.76	96.65
Free Cash Flow Growth	64.34%	-18.73%	-3.48%	42.53%	67.43%
Free Cash Flow Margin	35.83%	26.49%	29.92%	32.16%	34.38%
Free Cash Flow Per Share	10.20	6.21	7.64	7.92	5.55
Cash Interest Paid	0.6	0.18	1.09	1.52	0.84
Cash Income Tax Paid	42.53	51.96	57.75	27.63	16.57
Levered Free Cash Flow	144.82	41.28	71.04	105.3	67.11
Unlevered Free Cash Flow	145.21	41.4	71.72	106.25	67.69
Change in Working Capital	-13.36	-13.11	-40.5	-16.89	-10.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.